Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
A quick reference of all the mergers and acquisitions taking place within the global pharmaceuticals market.
January 31, 2024
By: Charlie Sternberg
The global pharmaceutical industry witnesses an excess of merger and acquisition (M&A) activity every year—probably more than most other industries—both in the number of deals and the amount of money spent on M&A.
From big game-changing deals to smaller yet still significant transactions, M&A is an integral part of the operations of pharma companies, especially as the cost of drug development consistently increases year-after-year.
Below is a frequently updated list of all the transactions that have taken place. Return often to stay informed on the latest deals occurring within the industry and to get a brief recap of the most important details.
Dive Deeper: Sign Up To Become An Industry Insider
Source BioScience UK Ltd, a provider of genomic services and histopathology diagnostics, completed its acquisition of Cambridge Clinical Laboratories (CCL), a provider of clinical, personalized healthcare testing services.
Date of announcement: April 10, 2025
Value: Not disclosed.
Curium, a nuclear medicine company, acquired Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.
PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, agreed to acquire a majority stake in Agilera Pharma AS from the Institute for Energy Technology (IFE) in Norway.
Date of announcement: April 9, 2025
Siemens AG signed an agreement to acquire Dotmatics, a provider of Life Sciences R&D software based in Boston, from Insight Partners.
Date of announcement: April 3, 2025
Value: $5.1 billion
Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, acquired Landmark Bio, a cell and gene therapy manufacturing company specializing in translational research, process development, and manufacturing technologies.
DHL Group acquired 100% of CRYOPDP, a specialty courier focused on clinical trials, biopharma, and cell and gene therapies.
Date of announcement: March 31, 2025
Curium Pharma, a developer, manufacturer, and distributor of nuclear medicine, acquired Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a nuclear medicine player headquartered in Istanbul, Turkey.
Date of announcement: March 28, 2025
Advanced Instruments, a Particia Industry subsidiary, has acquired and merged with Nova Biomedical. The combined company will operate under the Nova Biomedical name.
Date of announcement: March 19, 2025
iOncologi has acquired TargImmune Therapeutics to expand and strengthen its immunotherapy pipeline against solid tumors.
Date of announcement: March 17, 2025
Thermo Fisher Scientific Inc. entered into a definitive agreement to acquire Solventum’s Purification & Filtration business.
Date of announcement: February 25, 2025
Value: $4.1 billion
GSK plc completed its acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST).
Date of announcement: February 24, 2025
Value: $1.15 billion
Maravai LifeSciences Inc., a provider of life science reagents and services to researchers and biotech innovators, completed its acquisition of Officinae Bio’s DNA and RNA business.
Value: undisclosed
Flourish Research, a multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas, acquired Diablo Clinical Research, a multi-therapeutic clinical research facility performing phase I-IV clinical trials and medical device studies.
Date of announcement: February 18, 2025
Novartis agreed to acquire Anthos Therapeutics Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Date of announcement: February 11, 2025
Value: $925 million upon closing, plus potential additional payments of up to $2.15 billion
Bain Capital, a global private investment firm, signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group Corporation. The investment values the business at approximately $3.3 billion.
Date of announcement: February 10, 2025
Jabil Inc., a provider of engineering, manufacturing, and supply chain solutions, acquired Pharmaceutics International Inc. (Pii), a contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.
Date of announcement: February 4, 2025
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) with facilities in Belgium, Spain, the Netherlands, and Sweden, completed its acquisition of Catalent’s drug product manufacturing facility in Somerset, New Jersey.
Cormica, a global medical device and pharmaceuticals testing group, acquired Focus Laboratories, a microbiological testing firm with facilities in Allentown, PA, and Palm Harbor, FL.
Date of announcement: January 28, 2025
Lantheus Holdings Inc., a radiopharmaceutical-focused company, agreed to acquire Evergreen Theragnostics Inc., a clinical-stage radiopharmaceutical company.
Value: $250 million and up to an additional $752.5 million in potential milestone payments.
Medix Biochemica, a supplier of critical raw materials for the in vitro diagnostics (IVD) industry, acquired Candor Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions.
Date of announcement: January 22, 2025
FUJIFILM Irvine Scientific, Inc., a global provider for the manufacture of cell culture solutions for the life science and medical markets, agreed to sell its Medical Media Business Unit (MBU) to Astorg, a European private equity firm with a focus on global healthcare investments.
Date of announcement: January 21, 2025
Cormica, an expert in life sciences testing and consulting, acquired Zwisler Laboratorium, a provider of laboratory services headquartered in Reichenau, Germany.
Date of announcement: January 20, 2025
Cube Biotech and IBA Lifesciences, two innovators in the biotechnology industry, merged to create a unified entity dedicated to advancing research and production capabilities for the life science industry.
Date of announcement: January 14, 2025
GSK plc agreed to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.
Date of announcement: January 13, 2025
Value: $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment
Johnson & Johnson agreed to acquire all outstanding shares of Intra-Cellular Therapies Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders.
Value: $14.6 billion
Canyon Labs agreed to acquire iuvo BioScience’s laboratory services and scientific consulting divisions, enabling both companies to accelerate their specialized growth trajectories.
Date of announcement: January 7, 2025
Molex, a parent to Phillips Medisize, completed, through an affiliate, the acquisition of Vectura Group Ltd. from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International Inc.
Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, acquired Nektar Therapeutics’ PEGylation reagent manufacturing business. Date of announcement: December 2, 2024 Value: undisclosed
CBC Group, a healthcare-dedicated asset management firm, acquired UCB’s mature neurology and allergy business in China in partnership with Mubadala Investment Company. Date of announcement: December 2, 2024 Value: undisclosed
Poseida Therapeutics Inc., a clinical-stage allogeneic cell therapy and genetic medicines company, entered into a merger agreement to be acquired by Roche Holdings Inc. Date of announcement: December 2, 2024 Value: $1.5 billion
Adragos Pharma, a global CDMO headquartered in Munich, Germany, acquired Baccinex, a Swiss-based provider of aseptic fill-finish manufacturing. Date of announcement: November 26, 2024 Value: undisclosed
Arlington Capital Partners, a Washington, D.C.-area private investment firm specializing in government-regulated industries, acquired TEAM Technologies Inc., a global manufacturer of essential healthcare products, from Clearlake Capital Group. Date of announcement: November 25, 2024 Value: undisclosed
Novartis acquired Kate Therapeutics, a San Diego-based, preclinical stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat neuromuscular diseases. Date of announcement: November 21, 2024 Value: $1.1 billion
Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, acquired PrimeFour Therapeutics’ portfolio of novel nucleoside analogs. Date of announcement: November 11, 2024 Value: undisclosed
Maravai LifeSciences Inc., a global provider of life science reagents and services to researchers and biotech innovators, signed an agreement to acquire the DNA and RNA business of Officinae Bio. Date of announcement: November 8, 2024 Value: undisclosed
Concept Life Sciences (CLS), a UK-based drug discovery, development, and manufacturing organization backed by Limerston Capital, acquired Charnwood Discovery, a renowned UK-based drug discovery research firm. Date of announcement: November 5, 2024 Value: undisclosed
Kapoose Creek Bio, a biotechnology company leveraging AI for drug discovery, acquired an exclusive license to Adapsyn Bioscience’s chemical informatics platform, and acquired its drug discovery lab and talent. Date of announcement: October 30, 2024 Value: undisclosed
AbbVie entered a definitive agreement to acquire Aliada, a biotechnology company developing therapies using a novel blood-brain barrier (BBB)–crossing technology for central nervous system (CNS) diseases. Date of announcement: October 29, 2024 Value: $1.4 billion
Modifi Biosciences Inc., a developer of direct DNA modification-enabled cancer therapeutics, was acquired by Merck. Date of announcement: October 23, 2024 Value: $1.3 billion
Cold Chain Technologies (CCT), a global provider of advanced thermal packaging and digital monitoring solutions for the transportation of temperature-sensitive life sciences products, acquired Tower Cold Chain, a global provider of advanced passive reusable cold chain solutions. Date of announcement: October 23, 2024 Value: Undisclosed
PDC, supported by Vance Street Capital, finalized its acquisition of Resenex to provide fluid management solutions focused on supporting the development and production needs of the healthcare and biotechnology sectors. Date of announcement: October 16, 2024 Value: undisclosed
The acquisition of Longboard marks a strategic milestone for Lundbeck, enhancing and complementing its Focused Innovator strategy and advancing its goal of building a neuro-rare disease franchise. Date of announcement: October 15, 2024 Value: $2.6 billion
The KD Pharma Group, a CDMO specializing in pharmaceutical and nutritional lipids, completed its acquisition of dsm-firmenich’s Marine Lipids business. Date of announcement: October 1, 2024 Value: undisclosed
Nivagen Pharmaceuticals, Inc., a specialty pharmaceuticals company, sold its MedisourceRx business unit to Hims & Hers Health, Inc., a prominent health and wellness company. Date of announcement: September 23, 2024 Value: undisclosed
Telix Pharmaceuticals Limited agreed to acquire RLS, a Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, from its parent company, RLS Group Ltd. Date of announcement: September 23, 2024 Value: $230 million
Agilent Technologies Inc. completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. Date of announcement: September 23, 2024 Value: $925 million
Gale Process Solutions (GPS), a division of International Process Plants (IPP) that designs and fabricates alloy process equipment, finalized its acquisition of the Porcupine Processor brand of specialty dryers for the process industry. Date of announcement: September 17, 2024 Value: undisclosed
Molex, a parent to Phillips Medisize, signed an agreement to purchase Vectura Group Limited, a leader in inhalation drug device design and formulation based in Chippenham, UK, from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International (PMI). Date of announcement: September 17, 2024 Value: undisclosed
Gentronix, a UK-based contract research organization (CRO) specializing in genetic toxicology, was acquired by Scantox Group of Denmark. Date of announcement: September 9, 2024 Value: undisclosed
Olon, a chemical-pharmaceutical group, announced plans to acquire HuvePharma Italia Srl and its site in Garessio, (Cuneo, Italy). Date of announcement: September 4, 2024 Value: undisclosed
Bora Pharmaceuticals Co., Ltd. made a strategic investment in Tanvex Biopharma Co., Ltd., under which Bora Biologics, a subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities to create a global service for biologics development and supply. Date of announcement: August 28, 2024 Value: undisclosed
VION Biosciences, a life science platform company, acquired Echelon Biosciences, a supplier of critical lipid-based excipients. Date of announcement: August 23, 2024 Value: undisclosed
Visiox Pharmaceuticals Inc. entered into a definitive merger agreement with Ocuvex Therapeutics Inc., a privately held ophthalmic pharmaceutical company that boasts a robust pipeline of near-term ophthalmic medicines. Date of announcement: August 19, 2024 Value: undisclosed
Eli Lilly and Co. completed its acquisition of Morphic Holding, Inc., a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). Date of announcement: August 16, 2024 Value: $3.2 billion
Crown Laboratories Inc., a privately held skincare company, and Revance Therapeutics, Inc., a biotechnology company, entered into a merger agreement under which the companies seek to merge the two complementary organizations. Date of announcement: August 14, 2024 Value: $924 million
Mallinckrodt plc and CVC Capital Partners entered into a definitive agreement under which CVC Capital Partners Fund IX will acquire the company’s Therakos business. Date of announcement: August 7, 2024 Value: $925 million
AbbVie completed its acquisition of Cerevel Therapeutics—strengthening its foundation in neuroscience and positioning itself to deliver sustainable long-term performance. Date of announcement: August 2, 2024 Value: $8.7 billion
Otsuka Pharmaceutical Co., Ltd. and Jnana Therapeutics Inc. have entered into a definitive merger agreement under which Otsuka will acquire Jnana, making it a wholly owned subsidiary through Otsuka’s 100-percent owned subsidiary, Otsuka America, Inc. (OAI). Date of announcement: August 1, 2024 Value: $800 million
MilliporeSigma’s Life Science business closed its acquisition of Mirus Bio following regulatory clearances and the fulfillment of other customary closing conditions. Date of announcement: August 1, 2024 Value: $600 million
Boehringer Ingelheim acquired Nerio Therapeutics Inc. The company aims to develop Neiro’s innovative preclinical program as a potential key centerpiece component for its immuno-oncology portfolio.
Date of announcement: July 29, 2024
Value: $1.3 billion
Roche completed its acquisition of Carmot Therapeutics, a clinical-stage biotechnology company developing therapeutics for metabolic diseases.
Value: $2.7 billion
Agilent Technologies has signed a definitive agreement to acquire BioVectra, a specialized contract development and manufacturing organization (CDMO), for $925 million.
Date of announcement: July 24, 2024
Value: $925 million
MidEuropa signed an agreement to acquire a controlling stake in Famar, a pharmaceutical contract development and manufacturing organization (CDMO), from ECM Partners and Metric Capital Partners.
Date of announcement: July 23, 2024
Biolyst Scientific recently announced a new brand name, reflecting the integration of Electron Microscopy Sciences (EMS) and Azer Scientific.
Date of announcement: July 22, 2024
Agilent Technologies Inc. signed a definitive agreement to acquire BIOVECTRA, a specialized contract development and manufacturing organization (CDMO).
Value: Up to $925 million
Merck, known as MSD outside of the United States and Canada, completed the previously announced acquisition of Eyebiotech Limited (EyeBio).
Date of announcement: July 12, 2024
Value: Up to $3 billion
Thermo Fisher Scientific Inc. completed its acquisition of Olink Holding AB, a provider of next-generation proteomics solutions.
Date of announcement: July 10, 2024
Value: $3.1 billion
Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.
Date of announcement: July 8, 2024
MedPharm, a global topical and transdermal CDMO and an Ampersand Capital Partners portfolio company, is merging with Tergus Pharma, a Great Point Partners portfolio company.
Olon Group acquired GTP Bioways Group, a French company operating as Biotech CDMO and specializing in R&D services, process development and production of mAbs, enzymes, proteins, nanodrugs, ADCs and fill-finish.
Date of announcement: July 3, 2024
Alcon, a global leader in eye care, has acquired BELKIN Vision, including BELKIN Vision’s Direct Selective Laser Trabeculoplasty (DSLT) technology, expanding Alcon’s glaucoma portfolio with a first-line therapy.
Date of announcement: July 1, 2024
Value: $81 million
Rhenopharma Group has acquired Konapharma AG, a Swiss contract manufacturer for the pharmaceutical industry. Within the new group of companies, Konapharma now complements the services of packaging company Allpack and Rhenochem.
Date of announcement: June 27, 2024
CatSci Ltd, an innovation partner for medicines development, has acquired Reach Separations, a specialist chromatography provider for the analysis and purification of therapeutics.
Date of announcement: June 26, 2024
ANI Pharmaceuticals Inc. agreed to acquire Alimera Sciences Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with maintaining better vision longer.
Date of announcement: June 24, 2024Value: $381 million
Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, acquired Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization (CDMO) based in Ilsenburg, Germany.
Date of announcement: June 13, 2024Value: undisclosed
Ono Pharmaceutical Co. Ltd. completed its previously announced tender offer to acquire all outstanding shares of common stock of U.S. biopharmaceutical company Deciphera Pharmaceuticals Inc. through its wholly-owned subsidiary, Topaz Merger Sub Inc.
Date of announcement: June 12, 2024Value: $2.4 billion
The EQT Healthcare Growth Strategy and the EQT Growth Fund agreed to acquire a majority stake in CluePoints, with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA.
Date of announcement: June 12, 2024Value: undisclosed
One of Aterian Investment Partners’ affiliates closed its acquisition of Contract Pharmaceuticals Ltd. Canada, a North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
Date of announcement: June 6, 2024Value: Undisclosed
Formosa Laboratories, Inc., an API supplier and CDMO headquartered in Taiwan, completed its acquisition of SynChem, Inc., a contract research laboratory located in suburban Chicago. SynChem will now operate under the new name SynChem-Formosa.
Date of announcement: June 4, 2024Value: Undisclosed
Merck, known as MSD outside of the United States and Canada, entered into a definitive agreement under which it will acquire Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company.
Date of announcement: May 29, 2024Value: $3 billion
Asahi Kasei Corp. offered to acquire the shares of the pharmaceutical company Calliditas Therapeutics AB to make Calliditas a wholly-owned subsidiary of Asahi Kasei.
Date of announcement: May 28, 2024Value: $1.1 billion
Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA), has acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics.
Date of announcement: May 23, 2024Value: Undisclosed
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, signed a definitive agreement to acquire Mirus Bio.
Date of announcement: May 23, 2024Value: $600 million
Biogen Inc. and Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), entered into a definitive agreement under which Biogen will acquire HI-Bio.
Date of announcement: May 22, 2024Value: $1.15 billion upfront and up to $650 million in potential milestone payments
Johnson & Johnson entered a definitive agreement to acquire Proteologix Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases.
Date of announcement: May 16, 2024Value: $850 million in cash, with potential for an additional milestone payment
Selvita S.A. completed its strategic acquisition of PozLab, a CDMO offering drug product development services and small pilot plant capabilities, including analytical, formulation, and process development competencies, followed by microbiological testing.
Date of announcement: May 7, 2024Value: Undisclosed
LSL Pharma Group Inc., a Canadian integrated pharmaceutical company, entered into a binding Letter of Intent to acquire Target Co., a privately held, Quebec-based competing contract drug manufacturer (CDMO) specialized in the formulation, production, and marketing of natural products.
Date of announcement: May 6, 2024Value: $2.5 million
Novartis agreed to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, MA focused on developing radioligand therapies (RLTs) to treat cancers.
Date of announcement: May 3, 2024Value: $1 billion upfront + $750 million in payments upon completion of pre-specified milestones
Myonex completed the acquisition of Creapharm’s pharmaceutical services business.
Date of announcement: May 2, 2024Value: Undisclosed
Deciphera Pharmaceuticals LLC., a biopharmaceutical company, entered into a definitive merger agreement with Ono Pharmaceutical Company, Ltd. (ONO) under which ONO will acquire all outstanding shares of Deciphera common stock in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO.
Date of announcement: April 29, 2024Value: $2.4 billion
Eli Lilly and Company agreed to acquire a manufacturing facility from Nexus Pharmaceuticals, a leading sterile manufacturer in the pharmaceutical industry.
Date of announcement: April 24, 2024Value: Undisclosed
Kühne Holding AG agreed to acquire pharma contract development and manufacturing organization Aenova Group from international investment firm BC Partners.
Incyte Corp. entered into a definitive agreement to acquire Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing small molecules for systemic immune and neuro-immune disorders.
Date of announcement: April 23, 2024Value: $750 million plus Escient’s net cash remaining at the close of the transaction
Qinecsa Solutions, a provider of technology pharmacovigilance solutions, acquired Insife ApS (Insife), a Danish-based software, technology, and consultancy firm specializing in developing pharmacovigilance platforms.
Date of announcement: April 11, 2024Value: Undisclosed
Eliem Therapeutics Inc. and Tenet Medicines Inc., a development-stage private biotechnology company, have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet.
Date of announcement: April 11, 2024Value: $210 million
Vertex Pharmaceuticals Inc. and Alpine Immune Sciences Inc., a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share.
Date of announcement: April 11, 2024Value: $4.9 billion
Essential Pharma, an international specialty pharma group, completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd., a clinical stage pharmaceutical company focused on the development of life-changing therapies in pediatric rare disease.
Date of announcement: April 9, 2024Value: $130 million
Date of announcement: April 5, 2024Value: $13.1 billion
Date of announcement: April 3, 2024Value: Undisclosed
Date of announcement: April 3, 2024Value: $1.8 billion
Bora Pharmaceuticals Co., Ltd. completed the acquisition of Upsher-Smith Laboratories, LLC., a generics manufacturer and marketer based in Minnesota, from its sellers, Sawai Group Holdings and Sumitomo Corp. of Americas.
Date of announcement: April 2, 2024Value: $210 million
Veeda Clinical Research Ltd., a full-service contract research organization (CRO), acquired Heads, a privately held European CRO specializing in conducting clinical trials in oncology.
Date of announcement: March 26, 2024Value: Undisclosed
Novo Nordisk agreed to acquire Cardior Pharmaceuticals, an expert in the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart.
Date of announcement: March 25, 2024Value: $1.12 billion
AbbVie Inc. agreed to acquire Landos Biopharma Inc., a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
Date of announcement: March 25, 2024Value: $137.5 million
Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, acquired Biologos LLC, a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera.
Date of announcement: March 20, 2024Value: Undisclosed
AstraZeneca entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
Date of announcement: March 19, 2024Value: $2.4 billion
Bristol Myers Squibb completed its acquisition of Karuna Therapeutics, Inc. Karuna is now a wholly owned subsidiary of BMS.
Date of announcement: March 18, 2024Value: $14 billion
AstraZeneca entered a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing treatments for rare endocrine diseases.
Date of announcement: March 14, 2024Value: $1.05 billion
Novartis exercised its option to acquire all outstanding capital stock of IFM Due, a subsidiary company of IFM developing small molecules that inhibit the cGAS-STING pathway.
Date of announcement: March 13, 2024Value: $90 million upfront plus up to $745 million in milestones
Johnson & Johnson acquired Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs).
Date of announcement: March 7, 2024Value: $2 billion
Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, acquired Ness Therapeutics Inc in an all-equity transaction.
Date of announcement: March 4, 2024Value: Undisclosed
CoreRx Inc. agreed to acquire Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.
Date of announcement: February 29, 2024Value: $130M
Ginkgo Bioworks acquired Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32.
Date of announcement: February 28, 2024Value: Undisclosed
Ginkgo Bioworks acquired Proof Diagnostics, an innovative life sciences tools, diagnostics and computational discovery company which uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases.
Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC, a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas.
Date of announcement: February 27, 2024Value: $8M upfront + milestone payments
AstraZeneca successfully completed its acquisition of Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition.
Date of announcement: February 23, 2024Value: Undisclosed
Telix agreed to acquire QSAM Biosciences Inc.—a U.S.-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer—and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).
Date of announcement: February 13, 2024Value: Undisclosed
Chanelle Pharma, Ireland’s largest indigenous manufacturer of generic pharmaceuticals for animal and human health, was sold by its founder Michael H Burke to Exponent, a private equity firm.
BioVaxys Technology Corp. acquired the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology, developed by IMV Inc., Immunovaccine Technologies Inc., and IMV USA (IMV).
Date of announcement: February 12, 2024Value: $750,000 upfront cash payment
AbbVie completed its acquisition of ImmunoGen Inc., which is now part of AbbVie, gaining its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
Date of announcement: February 12, 2024Value: Not disclosed
Gilead Sciences Inc. entered a definitive agreement under which it will acquire CymaBay Therapeutics Inc.
Date of announcement: February 12, 2024Value: $4.3 billion
Jazz Pharmaceuticals plc and Redx Pharma plc signed a definitive agreement under which Jazz will acquire Redx’s KRAS (Kirsten rat sarcoma virus) inhibitor program.
Date of announcement: February 8, 2024Value: $10 million upfront
Novartis entered an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing oncology medicines.
Date of announcement: February 6, 2024Value: €2.7 billion ($2.9 billion)
Catalent Inc., a global CDMO headquartered in New Jersey, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction.
Date of Announcement: February 5, 2024Value: $16.5 billion
Biologics CDMOs Biovian and 3P Biopharmaceuticals combined with the aim of establishing a new pan-European leader in their field.
Date of Announcement: February 2, 2024Value: Gross sales exceed $81 million
Regeneron Pharmaceuticals Inc. formed Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc., under which it acquired full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities.
Date of Announcement: January 30, 2024Value: $5 million and a single milestone payment
Avrobio Inc., a clinical stage gene therapy company, and Tectonic Therapeutic Inc., a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, entered into a definitive merger agreementto combine in an all-stock transaction.
Date of Announcement: January 30, 2024Value: Not disclosed
Oxford Biomedica plc, a quality and innovation-led cell and gene therapy CDMO, completed its previously announced acquisition of ABL Europe SAS from Institut Mérieux SA.
Date of Announcement: January 29, 2024Value: $16.3 million
Bruker Corp. entered a definitive agreement to acquire Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions.
Date of Announcement: January 25, 2024Value: Not disclosed
Sandoz, a generic and biosimilar medicines company, signed an agreement to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc.
Date of Announcement: January 24, 2024Value: $170 million upfront
Sanofi entered into a definitive agreement under which its subsidiary Aventis Inc. will acquire all assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently in a registrational trial for the treatment of alpha-1 antitrypsin deficiency (AATD).
Date of Announcement: January 24, 2024Value: $2.2 billion
Bora Pharmaceuticals acquired Upsher-Smith Laboratories, a generics manufacturer based in Minnesota.
Date of Announcement: January 23, 2024Value: $210 million
Alcami Corporation, a contract development and manufacturing organization (CDMO), completed the acquisition of Pacific Pharmaceutical Services (PPS), a preferred provider of cGMP pharma storage and services.
Date of Announcement: January 19, 2024Value: Not disclosed
iuvo BioScience, a specialty PRO (Partner Research Organization) providing preclinical and clinical development services, lab services, and scientific consulting, acquired Promedica International, a California Corp. (PMI), a specialty ophthalmology-focused clinical CRO.
Date of Announcement: January 18, 2024Value: Not disclosed
Kindeva Drug Delivery acquired Summit Biosciences Inc., an intranasal drug-delivery CDMO, adding a new drug-delivery platform and further expanding Kindeva’s capabilities across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).
Merck entered into a definitive agreement to acquire Harpoon Therapeutics Inc., which has a portfolio of novel T-cell engagers that employ the company’s Tri-specific T cell Activating Construct (TriTAC) platform.
Date of Announcement: January 9, 2024Value: $680 million
Johnson & Johnson entered into a definitive agreement to acquire Ambrx Biopharma Inc., a clinical-stage biopharmaceutical company with a synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs).
Date of Announcement: January 9, 2024Value: $2 billion
GSK plc entered into an agreement to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company focused on treatments for certain respiratory and inflammatory conditions.
Date of Announcement: January 9, 2024Value: $1 billion upfront and as much as $400 million in success-based regulatory milestones
Novartis AG entered an agreement to acquire Calypso Biotech BV, a developer of Interleukin15 (IL-15) targeted therapies.
Date of Announcement: January 8, 2024Value: $250 million upfront upon closing and potential development milestones of up to $175 million
SanReno Therapeutics, a clinical-stage company specializing in the discovery, development, and commercialization of therapies for kidney diseases, has been acquired by Novartis. SanReno will become an indirect, wholly owned subsidiary of Novartis.
Date of Announcement: January 5, 2024Value: Not disclosed
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
